We are also pleased to share updates on our R&D pipeline—both today and at our ... the last patient in the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome anticipated in the ...
Acadia is evaluating its pipeline candidate, ACP-101, in the phase III COMPASS PWS study for the treatment of Prader-Willi Syndrome (PWS). Enrollment of the last patient in the study is likely to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback